Saturday 17 October 2026
Export LSDIF’s income statement to Excel — free account
Lucy Scientific Discovery Inc.
LSDIF Healthcare Drug Manufacturers Specialty & Generic
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow LSDIF
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 1.75 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 40.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 2 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | 35.71 | |||||
| EBT | — | — | — | — | — | — | (4) | (5) | (6) | (9) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (128,407.14) | |||||
| Net income | — | — | — | — | — | — | (3) | (5) | (6) | (9) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.01 | ||||
| Earnings | — | — | — | — | — | — | (0.19) | (0.29) | (6.80) | (7.10) | |||||
| Cash flow | — | — | — | — | — | — | (0.03) | (0.09) | (2.81) | (3.36) | |||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | (0.04) | (0.21) | |||||
| Free cash flow | — | — | — | — | — | — | (0.03) | (0.09) | (2.85) | (3.57) | |||||
| Book value | — | — | — | — | — | — | (0.27) | (0.40) | (5.55) | 3.68 | |||||
| Shares, m | — | — | — | — | — | — | 16 | 16 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 3.12 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (3.39) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | 0 | (1) | (2) | (4) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | 0 | (1) | (2) | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (4) | (4) | (4) | 1 | ||||
| Total debt | — | — | — | — | — | — | 1 | 2 | 3 | 1 | |||||
| Net debt | — | — | — | — | — | — | 1 | 2 | 3 | (2) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (4) | (6) | (5) | 5 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (166.57) | (114.98) | (134.06) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (121.55) | |||||
| ROE | — | — | — | — | — | — | 0.00 | 88.39 | 105.19 | 18,140.26 | |||||
Negative figures in brackets.
Fiscal years to Jun 2023 · latest quarter Dec 2023
Charts ten years each
Lucy Scientific Discovery Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AKAN Akanda Corp. | $3.5M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| PRFX PainReform Ltd. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| IMCC IM Cannabis Corp. | $2.2M | — (loss-making) | — (loss-making) | −40.28% (below 0%: shrinking) | n/m | −266.81% (below 0%: shrinking) | 19.83% | (27.54%) | Compare |
| NEPTF Neptune Wellness Solutions Inc. | $1.6M | — (loss-making) | — (loss-making) | −37.75% (below 0%: shrinking) | n/m | +53.44% (above 0%: growing) | 13.62% | (232.88%) | Compare |
| PTPI Petros Pharmaceuticals, Inc. | $1.0M | — (loss-making) | — (loss-making) | +1,070.55% (above 0%: growing) | n/m | +71.27% (above 0%: growing) | 73.82% | 0.00% | Compare |
| SBFM Sunshine Biopharma, Inc. | $990.0K | — (loss-making) | — (loss-making) | −1.56% (below 0%: shrinking) | n/m | +49.38% (above 0%: growing) | 26.20% | (17.41%) | Compare |
| LSDIF Lucy Scientific Discovery Inc. | $900.0K | — (loss-making) | — | — | n/m | −493.98% (below 0%: shrinking) | 59.79% | (8,891.75%) | |
| SXTC China SXT Pharmaceuticals, Inc. | $710.0K | — (loss-making) | — (loss-making) | −16.76% (below 0%: shrinking) | +92.67% (above 0%: growing) | −107.59% (below 0%: shrinking) | 44.09% | 0.00% | Compare |
| Median of peers | $1.9M | — | — | −9.16% | — | +50.45% | 23.02% | (8.70%) |
Lucy Scientific Discovery Inc. (LSDIF) key facts
- Lucy Scientific Discovery Inc. (LSDIF) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector.
- Return on equity was 18,140.3% and debt-to-equity 0.00.
- Its Altman Z-score is −6.99 (distress zone) for fiscal 2023.